ArticleMolecular genetics and genomics : MGG2026
Morinda officinalis polysaccharide improves osteoporosis by enhancing m⁶A-modified SOCS5 mRNA stability via regulating the hsa_circ_0001165/IGF2BP2 axis.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis (OP) is a prevalent bone metabolic disorder. Bone marrow mesenchymal stem cells (BMSCs) serve as key cellular mediators in bone remodeling through their capacity to differentiate into bone-forming osteoblasts, positioning them as promising targets for therapeutic intervention. Morinda officinalis polysaccharide (MOP) is a bioactive compound with medicinal potential. This study aimed to investigate the role and molecular mechanism of MOP in the progression of OP in vitro and in vivo, specifically through promoting osteogenic differentiation of BMSCs. An OP cell model was established by treating BMSCs with 4 µM dexamethasone (DEX). Following DEX induction, cells were treated with various concentrations of MOP. Cell viability was assessed using the Cell Counting Kit-8 assay, while proliferation was assessed through Ki67 immunostaining. Apoptotic and cell cycle distribution were analyzed by flow cytometric. Osteogenic differentiation was examined using Alkaline Phosphatase staining and Alizarin Red S staining. The regulatory relationships among hsa_circ_0001165, insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), and suppressor of cytokine signaling 5 (SOCS5) were validated through RNA Immunoprecipitation, RNA pull-down, and methylated RNA immunoprecipitation quantitative PCR assays. Furthermore, an OP rat model was established by intramuscular injection of 5 mg/kg DEX twice weekly for 6 weeks. Rats were subsequently treated with different doses of MOP by gavage for 8 weeks, after which bone mineral density, bone histomorphology, and osteogenic marker expression were evaluated. MOP dose-dependently reversed the DEX-induced suppression of BMSC proliferation, cell cycle progression, and osteogenic differentiation, and also reduced apoptosis. MOP upregulated hsa_circ_0001165 expression; knockdown of hsa_circ_0001165 attenuated these promotive effects of MOP on BMSC proliferation and osteogenic differentiation. Hsa_circ_0001165 directly interacted with the IGF2BP2 protein, thereby enhancing the stability of SOCS5 mRNA. Similarly, knockdown of SOCS5 diminished the enhancing effects of MOP on BMSC proliferation and osteogenic differentiation. Additionally, in vivo results demonstrated that MOP significantly improved bone mineral density (BMD), trabecular bone structure, and osteogenic marker expression in OP rats. MOP alleviates OP by upregulating an hsa_circ_0001165/IGF2BP2 axis, which stabilizes m⁶A-modified SOCS5 mRNA and consequently promotes BMSC osteogenic differentiation.
Indexed as
Identifiers
41843192What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.